These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 25985292)

  • 41. Unveiling transient protein-protein interactions that modulate inhibition of alpha-synuclein aggregation by beta-synuclein, a pre-synaptic protein that co-localizes with alpha-synuclein.
    Janowska MK; Wu KP; Baum J
    Sci Rep; 2015 Oct; 5():15164. PubMed ID: 26477939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of fluorescent labeling on α-synuclein fibril morphology.
    Mučibabić M; Apetri MM; Canters GW; Aartsma TJ
    Biochim Biophys Acta; 2016 Oct; 1864(10):1419-27. PubMed ID: 27475048
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DJ-1, a Parkinson's disease related protein, aggregates under denaturing conditions and co-aggregates with α-synuclein through hydrophobic interaction.
    Zhu M; H Patel S; Han S
    Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1759-1769. PubMed ID: 28330770
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Fundamental mechanisms of amyloid fibril formation by alpha-synuclein in Parkinson's disease: quantitative modelling].
    Galvagnion C; Buell AK
    Med Sci (Paris); 2015; 31(6-7):597-600. PubMed ID: 26152159
    [No Abstract]   [Full Text] [Related]  

  • 45. Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy.
    Jiang TF; Zhang YJ; Zhou HY; Wang HM; Tian LP; Liu J; Ding JQ; Chen SD
    J Neuroimmune Pharmacol; 2013 Mar; 8(1):356-69. PubMed ID: 23325107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species.
    González-Lizárraga F; Socías SB; Ávila CL; Torres-Bugeau CM; Barbosa LR; Binolfi A; Sepúlveda-Díaz JE; Del-Bel E; Fernandez CO; Papy-Garcia D; Itri R; Raisman-Vozari R; Chehín RN
    Sci Rep; 2017 Feb; 7():41755. PubMed ID: 28155912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
    Rutherford NJ; Moore BD; Golde TE; Giasson BI
    J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alpha-Synuclein Proximity Ligation Assay (AS-PLA) in Brain Sections to Probe for Alpha-Synuclein Oligomers.
    Roberts RF; Bengoa-Vergniory N; Alegre-Abarrategui J
    Methods Mol Biol; 2019; 1948():69-76. PubMed ID: 30771171
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Curcumin binds to the pre-fibrillar aggregates of Cu/Zn superoxide dismutase (SOD1) and alters its amyloidogenic pathway resulting in reduced cytotoxicity.
    Bhatia NK; Srivastava A; Katyal N; Jain N; Khan MA; Kundu B; Deep S
    Biochim Biophys Acta; 2015 May; 1854(5):426-36. PubMed ID: 25666897
    [TBL] [Abstract][Full Text] [Related]  

  • 50. α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease.
    Levine PM; Galesic A; Balana AT; Mahul-Mellier AL; Navarro MX; De Leon CA; Lashuel HA; Pratt MR
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1511-1519. PubMed ID: 30651314
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential aggregation properties of alpha-synuclein isoforms.
    Bungeroth M; Appenzeller S; Regulin A; Völker W; Lorenzen I; Grötzinger J; Pendziwiat M; Kuhlenbäumer G
    Neurobiol Aging; 2014 Aug; 35(8):1913-9. PubMed ID: 24629672
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent Updates in Curcumin Pyrazole and Isoxazole Derivatives: Synthesis and Biological Application.
    Mishra S; Patel S; Halpani CG
    Chem Biodivers; 2019 Feb; 16(2):e1800366. PubMed ID: 30460748
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Curcumin derivatives and Aβ-fibrillar aggregates: An interactions' study for diagnostic/therapeutic purposes in neurodegenerative diseases.
    Orteca G; Tavanti F; Bednarikova Z; Gazova Z; Rigillo G; Imbriano C; Basile V; Asti M; Rigamonti L; Saladini M; Ferrari E; Menziani MC
    Bioorg Med Chem; 2018 Aug; 26(14):4288-4300. PubMed ID: 30031653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trehalose inhibits fibrillation of A53T mutant alpha-synuclein and disaggregates existing fibrils.
    Yu WB; Jiang T; Lan DM; Lu JH; Yue ZY; Wang J; Zhou P
    Arch Biochem Biophys; 2012 Jul; 523(2):144-50. PubMed ID: 22575388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potent α-Synuclein Aggregation Inhibitors, Identified by High-Throughput Screening, Mainly Target the Monomeric State.
    Kurnik M; Sahin C; Andersen CB; Lorenzen N; Giehm L; Mohammad-Beigi H; Jessen CM; Pedersen JS; Christiansen G; Petersen SV; Staal R; Krishnamurthy G; Pitts K; Reinhart PH; Mulder FAA; Mente S; Hirst WD; Otzen DE
    Cell Chem Biol; 2018 Nov; 25(11):1389-1402.e9. PubMed ID: 30197194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distinct Mechanisms Determine α-Synuclein Fibril Morphology during Growth and Maturation.
    Sidhu A; Segers-Nolten I; Raussens V; Claessens MM; Subramaniam V
    ACS Chem Neurosci; 2017 Mar; 8(3):538-547. PubMed ID: 28292187
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Complexation of NAC-Derived Peptide Ligands with the C-Terminus of α-Synuclein Accelerates Its Aggregation.
    Jha NN; Ranganathan S; Kumar R; Mehra S; Panigrahi R; Navalkar A; Ghosh D; Kumar A; Padinhateeri R; Maji SK
    Biochemistry; 2018 Feb; 57(5):791-804. PubMed ID: 29286644
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Definition of a molecular pathway mediating α-synuclein neurotoxicity.
    Burré J; Sharma M; Südhof TC
    J Neurosci; 2015 Apr; 35(13):5221-32. PubMed ID: 25834048
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multistep Inhibition of α-Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine.
    Perni M; Flagmeier P; Limbocker R; Cascella R; Aprile FA; Galvagnion C; Heller GT; Meisl G; Chen SW; Kumita JR; Challa PK; Kirkegaard JB; Cohen SIA; Mannini B; Barbut D; Nollen EAA; Cecchi C; Cremades N; Knowles TPJ; Chiti F; Zasloff M; Vendruscolo M; Dobson CM
    ACS Chem Biol; 2018 Aug; 13(8):2308-2319. PubMed ID: 29953201
    [TBL] [Abstract][Full Text] [Related]  

  • 60. α-Synuclein Dimers as Potent Inhibitors of Fibrillization.
    Kyriukha YA; Afitska K; Kurochka AS; Sachan S; Galkin M; Yushchenko DA; Shvadchak VV
    J Med Chem; 2019 Nov; 62(22):10342-10351. PubMed ID: 31625739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.